Were Analysts Bullish MEI Pharma, Inc. (NASDAQ:MEIP) This Week?

February 15, 2018 - By Richard Conner

 Were Analysts Bullish MEI Pharma, Inc. (NASDAQ:MEIP) This Week?

MEI Pharma, Inc. (NASDAQ:MEIP) Ratings Coverage

Among 3 analysts covering MEI Pharma (NASDAQ:MEIP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. MEI Pharma had 7 analyst reports since September 4, 2015 according to SRatingsIntel. On Friday, September 4 the stock rating was maintained by Wedbush with “Hold”. The firm has “Hold” rating given on Wednesday, September 6 by Stifel Nicolaus. The firm has “Buy” rating by Oppenheimer given on Wednesday, June 14. The company was maintained on Monday, June 26 by Oppenheimer. The stock of MEI Pharma, Inc. (NASDAQ:MEIP) earned “Buy” rating by Oppenheimer on Wednesday, August 2. The firm has “Buy” rating by Oppenheimer given on Wednesday, May 31. Below is a list of MEI Pharma, Inc. (NASDAQ:MEIP) latest ratings and price target changes.

06/09/2017 Broker: Stifel Nicolaus Rating: Hold New Target: $2.5 Maintain

The stock decreased 0.46% or $0.01 during the last trading session, reaching $2.16. About 20,324 shares traded. MEI Pharma, Inc. (NASDAQ:MEIP) has risen 20.90% since February 15, 2017 and is uptrending. It has outperformed by 4.20% the S&P500.

MEI Pharma, Inc., an oncology company, focuses on the clinical development of drugs for the treatment of cancer. The company has market cap of $80.03 million. The companyÂ’s clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. It currently has negative earnings. The Company’s clinical development portfolio also includes ME-401, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia or follicular lymphoma; and ME-344, an isoflavone-derived mitochondrial inhibitor for the treatment of HER2-negative breast cancer.

More notable recent MEI Pharma, Inc. (NASDAQ:MEIP) news were published by: Marketwatch.com which released: “MEI Pharma Inc.” on August 08, 2016, also Prnewswire.com with their article: “MEI Pharma Announces FDA Clearance of Investigational New Drug Application for …” published on January 08, 2018, Streetinsider.com published: “MEI Pharma (MEIP) Says Interim Data Review Supports Continuation of Clinical …” on February 13, 2018. More interesting news about MEI Pharma, Inc. (NASDAQ:MEIP) were released by: Seekingalpha.com and their article: “Helsinn Group and MEI Pharma announce that pracinostat has received ODD from …” published on January 11, 2018 as well as Prnewswire.com‘s news article titled: “MEI Pharma Announces Appointment of Brian Drazba as Chief Financial Officer” with publication date: April 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.